Lixivaptan is a highly potent, non-peptide, selective vasopressin V2 receptor antagonist. Lixivaptan antagonizes the action of vasopressin ( also known as antidiuretic hormone, ADH) on the V2 receptors in the kidney collecting duct, causing a decrease in renal water reabsorption and urine osmolality and an increase in urine volume.

The pharmacologic activity of Lixivaptan is expected to be of benefit in the treatment of disease states associated with water retention, such as congestive heart failure (CHF), cirrhosis and syndrome of inappropriate antidiuretic hormone ( SIADH ).

Because of its ability to cause the elimination of water with reduced sodium loss, Lixivaptan is expected to benefit patients by removing the excessive free water, while elevating plasma sodium, thus relieving signs and symptoms of hyponatremia and water retention.

How it works

Stage of Development

Click here to search the web for Lixivaptan